The effectiveness of subtenon triamcinolone injection for the treatment of macular edema in children with retinitis pigmentosa
- Authors: Katargina L.A.1, Denisova E.V.1, Khrabrova M.A.1, Osipova N.A.1
-
Affiliations:
- Helmholtz National Medical Research Center of Eye Diseases
- Issue: Vol 16, No 1 (2021)
- Pages: 5-12
- Section: Clinical studies
- Published: 15.01.2021
- URL: https://ruspoj.com/1993-1859/article/view/75776
- DOI: https://doi.org/10.17816/rpo2021-16-1-5-12
- ID: 75776
Cite item
Abstract
Aim: This study aimed to assess the functional and anatomical results of subtenon triamcinolone injections in children with retinitis pigmentosa (PR) and cystic macular edema (CME), refractory to local carbonic anhydrase inhibitors.
Material and methods: We examined 11 children (9 girls, 2 boys) aged 9 to 17 years who underwent subtenon injections of triamcinolone (22 eyes). The follow-up period ranged from 1.6 to 33.1 months (average 9.7±11.6 months), the number of triamcinalone injections ranged from 1 to 11, averaging 3. Before and after injection, best corrected visual acuity (BCVA), the thickness and structure of the retina in the macular zone (optical coherence tomography [OCT] was performed by using the NIDEK RS-3000, Japan or the Spectralis, Heidelberg Engineering, Germany), and intraocular pressure (IOP) were assessed.
Results: The CME height at the end of the observation period decreased in 10 cases (45.5%), and the average central retinal thickness decreased from 70 to 594 μm (on average, 219.1±183.4 μm). In 12 eyes (54.5%), the CME height at the end of the observation period did not change significantly. BCVA improved in two eyes (9.1%) and did not change in the other cases. Two children (18%) developed ophthalmic hypertension in both eyes after two injections of triamcinalone. In one child, IOP returned to normal on the background of hypothetical therapy. In another child, due to non-compensation of IOP at the maximum hypotensive mode, sinus trabeculectomy was performed in both eyes, and IOP normalization was achieved.
Conclusion: Subtenon injection of triamcinolone in children with CME against a background of PR is in most cases is an effective and safe method of treatment and can be recommended if carbonic anhydrase inhibitors are ineffective at reducing/ resorbing edema and maintaining or improving visual function. Considering that the action of triamcinolone is short lived, and its repeated injection is required, and the resorption of CME and an increase in visual acuity are not always achievable, it is necessary to continue the search for more effective treatment methods.
Full Text
About the authors
Lyudmila A. Katargina
Helmholtz National Medical Research Center of Eye Diseases
Email: katargina@igb.ru
MD, PhD, professor
Russian Federation, MoscowEkaterina V. Denisova
Helmholtz National Medical Research Center of Eye Diseases
Author for correspondence.
Email: deale_2006@inbox.ru
ORCID iD: 0000-0003-3735-6249
SPIN-code: 4111-4330
MD, PhD
Russian Federation, MoscowMaria A. Khrabrova
Helmholtz National Medical Research Center of Eye Diseases
Email: deale_2006@inbox.ru
ORCID iD: 0000-0001-9422-4264
MD, PhD student
Russian Federation, MoscowNatalia A. Osipova
Helmholtz National Medical Research Center of Eye Diseases
Email: natashamma@mail.ru
ORCID iD: 0000-0002-3151-6910
MD, PhD
Russian Federation, MoscowReferences
- Hamel C. Retinitis pigmentosa. Orphanet J Rare Dis. 2006;1:40. doi: 10.1186/1750-1172-1-40
- Verbakel SK, van Huet RA, Boon CJ, et al. Non-syndromic retinitis pigmentosa. Prog Retin Eye Res. 2018;66:157–186. doi: 10.1016/j.preteyeres.2018.03.005
- Hajali M, Fishman GA. The prevalence of cystoid macular oedema on optical coherence tomography in retinitis pigmentosa patients without cystic changes on fundus examination. Eye (Lond). 2008;23(4):915–919. doi: 10.1038/eye.2008.110
- Strong S, Liew G, Michaelides M. Retinitis pigmentosa-associated cystoid macularoedema: pathogenesis and avenues of intervention. Br J Ophthalmol. 2017;101(1):31–37. doi: 10.1136/bjophthalmol-2016-309376
- Barge S, Rothwell R, Sepúlveda P, et al. Intravitreal and subtenon depot triamcinolone as treatment of retinitis pigmentosa associated cystoid macular edema. Case Rep Ophthalmol Med. 2013;2013:591681. doi: 10.1155/2013/591681
- Artunay O, Yuzbasioglu E, Rasier R, et al. Intravitreal ranibizumab in the treatment of cystoid macularedema associated with retinitis pigmentosa. J Ocul Pharmacol Ther. 2009;25(6):545–550. doi: 10.1089/jop.2010.0044
- Giusti C, Forte R, Vingolo EM. Deflazacort treatmentof cystoid macular edema in patients affected by Retinitis Pigmentosa: a pilot study. Eur Rev Med Pharmacol Sci. 2002;6(1):1–8.
- Scorolli L, Morara M, Meduri A. Treatment of cystoidmacular edema in retinitis pigmentosa with intravitreal triamcinolone. Arch Ophthalmol. 2007;125(6):759–764. doi: 10.1001/archopht.125.6.759
- Ozdemir H, Karacorlu M, Karacorlu S. Intravitreal triamcinolone acetonide for treatment of cystoid macular oedema in patients with retinitis pigmentosa. Acta Ophthalmol Scand. 2005;83(2):248–251. doi: 10.1111/j.1600-0420.2005.00395.x
- Karasu B. Short-term outcomes of subtenon triamcinolone acetonide injections in patients with retinitis pigmentosa-associated cystoid macular edema unresponsive to carbonic anhydrase inhibitors. Int Ophthalmol. 2019;40(3):677–687. doi: 10.1007/s10792-019-01228-z
- Apushkin MA, Fishman GA, Grover S, et al. Rebound of cystoid macular edema with continued use of acetazolamide in patients with retinitis pigmentosa. Retina. 2007;27(8):1112–1118. doi: 10.1097/IAE.0b013e31805f6b79
- Liew G, Moore AT, Webster AR, et al. Efficacy and prognostic factors of response to carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2015;56(3):1531–1536. doi: 10.1167/iovs.14-15995
- Kitahata S, Hirami Y, Takagi S, et al. Efficacy of additional topical betamethasone in persistent cystoid macular oedema after carbonic anhydrase inhibitor treatments in retinitis pigmentosa. BMJ Open Ophthalmol. 2018;3(1):e000107. doi: 10.1136/bmjophth-2017-000107
- Schaal Y, Hondur AM, Tezel TH. Subtenon triamcinolone for cystoid macular edema due to retinitis pigmentosa unresponsive to oral acetazolamide. Can J Ophthalmol. 2016;51(4):e113–115. doi: 10.1016/j.jcjo.2015.12.021
- Saraiva VS, Sallum JM, Farah ME. Treatment of cystoid macular edema related to retinitis pigmentosa with intravitreal triamcinolone acetonide. Ophthalmic Surg Lasers Imaging. 2003;34(5):398–400. doi: 10.3928/1542-8877-20030901-11
- Fishman GA, Apushkin MA. Continued use of dorzolamide for the treatment of cystoid macular oedema in patients with retinitis pigmentosa. Br J Ophthalmol. 2007;91(6):743–745. doi: 10.1136/bjo.2006.107466
- Genead MA, Fishman GA. Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with retinitis pigmentosa and usher syndrome. Arch Ophthalmol. 2010;128(9):1146–1150. doi: 10.1001/archophthalmol.2010.172
- Grover S, Apushkin MA, Fishman GA. Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol. 2006;141(5):850–858. doi: 10.1016/j.ajo.2005.12.030
- Hagiwara A, Yamamoto S, Ogata K, et al. Macular abnormalities in patients with retinitis pigmentosa: prevalence on OCT examination and outcomes of vitreoretinal surgery. Acta Ophthalmol. 2011;89(2):122–125. doi: 10.1111/j.1755-3768.2010.01866.x
- Ikeda Y, Hisatomi T, Yoshida N, et al. The clinical efficacy of a topical dorzolamide in the management of cystoid macular edema in patients with retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol. 2012;250(6):809–814. doi: 10.1007/s00417-011-1904-5
- Mansour AM, Sheheitli H, Kucukerdonmez C, et al. Intravitreal dexamethasone implant in retinitis pigmentosa–related cystoid macular edema. Retina. 2018;38(2):413–423. doi: 10.1097/IAE.0000000000001542
- Melo GB, Farah ME, Aggio FB. Intravitreal injection of bevacizumab for cystoid macular edema in retinitis pigmentosa. Acta Ophthalmol Scand. 2007;85(4):461–443. doi: 10.1111/j.1600-0420.2006.00872.x
- Moustafa GA, Moschos MM. Intravitreal aflibercept (Eylea) injection for cystoid macular edema secondary to retinitis pigmentosa — a first case report and short review of the literature. BMC Ophthalmol. 2015;15:44. doi: 10.1186/s12886-015-0033-z
- Park UC, Park JH, Ma DJ, et al. A randomized paired-eye trial of intravitreal dexamethasone implant for cystoid macular edema in retinitis pigmentosa. Retina. 2019;40(7):1359–1366. doi: 10.1097/IAE.0000000000002589
- Querques G, Prascina F, Iaculli C, Noci ND. Intravitreal pegaptanib sodium (Macugen) for refractory cystoid macular edema in pericentral retinitis pigmentosa. Int Ophthalmol. 2007;29(2):103–107. doi: 10.1007/s10792-007-9175-1
- Garcia-Arumi J, Martinez V, Sararols L, et al. Vitreoretinal surgery for cystoid macular edema associatedwith retinitis pigmentosa. Ophthalmology. 2003;110(6):1164–1169. doi: 10.1016/S0161-6420(03)00259-8
- Fishman GA, Gilbert LD, Fiscella RG, et al. Acetazolamide for treatment of chronic macularedema in retinitis pigmentosa. Arch Ophthalmol. 1989;107(10):1445–1452. doi: 10.1001/archopht.1989.01070020519031
- Scruggs BA, Chen CV, Pfeifer W, et al. Efficacy of topical brinzolamide in children with retinal dystrophies. Ophthalmic Genet. 2019;40(4):350–358. doi: 10.1080/13816810.2019.1660381
- Fishman GA, Gilbert LD, Anderson RJ, et al. Effect of methazolamide on chronic macular edema in patients with retinitis pigmentosa. Ophthalmology. 1994;101(4):687–693. doi: 10.1016/s0161-6420(94)31277-2
- Srour M, Querques G, Leveziel N, et al. Intravitreal dexamethasone implant (Ozurdex) for macular edema secondary to retinitis pigmentosa Graefes Arch Clin Exp Ophthalmol. 2012;251(6):1501–1506. doi: 10.1007/s00417-012-2249-4
- Sudhalkar A, Kodjikian L, Borse N. Intravitreal dexamethasone implant for recalcitrant cystoid macular edema secondary to retinitis pigmentosa: a pilot study. Graefes Arch Clin Exp Ophthalmol. 2017;255(7):1369–1374. doi: 10.1007/s00417-017-3660-7
- Chung H, Hwang J, Kim J. Optical coherence tomography in the diagnosis and monitoring of cystoid macular edema in patients with retinitis. Retina. 2006;26(8):922–927. doi: 10.1097/01.iae.0000250008.83779.23